Yuqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuqi Wang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Fangli Weng
Department of Biology, Saint Louis University, St Louis, Missouri, USA
3 shared publicationsShan Huang
Department of Biology, Saint Louis University, St Louis, Missouri, USA
3 shared publicationsGabriela Soltys
Department of Biology, Saint Louis University, St Louis, Missouri, USA
2 shared publicationsGrace Lee
Biology, Saint Louis University, Saint Louis, Missouri, USA
2 shared publications- Guangyong Peng
Division of Infectious Diseases, Allergy & Immunology and Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
2 shared publications Matthew Stoeckel
Department of Biology, Saint Louis University, St Louis, Missouri, USA
2 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111402
Modulation of the stress-activated protein kinases Hog1/p38 and a TORC1-dependent kinase by curcumin is stress granule-dependent
- 25 March 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111402
Open AccessModulation of the stress-activated protein kinases Hog1/p38 and a TORC1-dependent kinase by curcumin is stress granule-dependent
- Open Access
- 30 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 408
Reconstructing Dynamic Gene Regulatory Networks Using f-Divergence from Time-Series scRNA-Seq Data
Inferring time-varying gene regulatory networks from time-series single-cell RNA sequencing (scRNA-seq) data remains a challenging task. The existing methods have notable limitations as most are either designed for reconstructing time-varying networks from bulk microarray data or constrained to inferring stationary networks from scRNA-seq data, failing to capture the dynamic regulatory changes at the single-cell level. Furthermore, scRNA-seq data present unique challenges, including sparsity, dropout events, and the need to account for heterogeneity across individual cells. These challenges complicate the accurate capture of gene regulatory network dynamics over time. In this work, we propose a novel f-divergence-based dynamic gene regulatory network inference method (f-DyGRN), which applies f-divergence to quantify the temporal variations in gene expression across individual single cells. Our approach integrates a first-order Granger causality model with various regularization techniques and partial correlation analysis to reconstruct gene regulatory networks from scRNA-seq data. To infer dynamic regulatory networks at different stages, we employ a moving window strategy, which allows for the capture of dynamic changes in gene interactions over time. We applied this method to analyze both simulated and real scRNA-seq data from THP-1 human myeloid monocytic leukemia cells, comparing its performance with the existing approaches. Our results demonstrate that f-DyGRN, when equipped with a suitable f-divergence measure, outperforms most of the existing methods in reconstructing dynamic regulatory networks from time-series scRNA-seq data.
- 30 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 408
Open AccessReconstructing Dynamic Gene Regulatory Networks Using f-Divergence from Time-Series scRNA-Seq Data
Inferring time-varying gene regulatory networks from time-series single-cell RNA sequencing (scRNA-seq) data remains a challenging task. The existing methods have notable limitations as most are either designed for reconstructing time-varying networks from bulk microarray data or constrained to inferring stationary networks from scRNA-seq data, failing to capture the dynamic regulatory changes at the single-cell level. Furthermore, scRNA-seq data present unique challenges, including sparsity, dropout events, and the need to account for heterogeneity across individual cells. These challenges complicate the accurate capture of gene regulatory network dynamics over time. In this work, we propose a novel f-divergence-based dynamic gene regulatory network inference method (f-DyGRN), which applies f-divergence to quantify the temporal variations in gene expression across individual single cells. Our approach integrates a first-order Granger causality model with various regularization techniques and partial correlation analysis to reconstruct gene regulatory networks from scRNA-seq data. To infer dynamic regulatory networks at different stages, we employ a moving window strategy, which allows for the capture of dynamic changes in gene interactions over time. We applied this method to analyze both simulated and real scRNA-seq data from THP-1 human myeloid monocytic leukemia cells, comparing its performance with the existing approaches. Our results demonstrate that f-DyGRN, when equipped with a suitable f-divergence measure, outperforms most of the existing methods in reconstructing dynamic regulatory networks from time-series scRNA-seq data.
- Top Cited Papers
- 12 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (785) , eadm7269
Tumor extracellular vesicle–derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming
The limited success of cancer immunotherapy has posed challenges in treating patients with cancer. However, promising strides could be made with a deeper understanding of the factors that cause T cell dysfunction within the tumor microenvironment and by developing effective strategies to counteract tumor-induced immune suppression. Here, we report that tumor-derived extracellular vesicles (tEVs) can induce senescence and suppression in T cells. Programmed death ligand 1 (PD-L1), a key component within tEVs, induced DNA damage and hyperactive lipid metabolism in both human and mouse T cells. This caused an elevated expression of lipid metabolic enzymes and an increase in cholesterol and lipid droplet formation, leading to cellular senescence. At a molecular level, PD-L1 derived from tEVs activated the cAMP-response element binding protein (CREB) and signal transducer and activator of transcription (STAT) signaling, which promoted lipid metabolism and facilitated senescence in human and mouse T cells. Inhibiting EV synthesis in tumors or blocking CREB signaling, cholesterol synthesis, and lipid droplet formation in effector T cells averted the tEV-mediated T cell senescence in vitro and in vivo in cell adoptive transfer and melanoma mouse models. The same treatments also bolstered the antitumor efficacy of adoptive transfer T cell therapy and anti–PD-L1 checkpoint immunotherapy in both human and mouse melanoma models. These studies identified mechanistic links between tumor-mediated immune suppression and potential immunotherapy resistance, and they provide new strategies for cancer immunotherapy.
- 12 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (785) , eadm7269
Top Cited PapersTumor extracellular vesicle–derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming
The limited success of cancer immunotherapy has posed challenges in treating patients with cancer. However, promising strides could be made with a deeper understanding of the factors that cause T cell dysfunction within the tumor microenvironment and by developing effective strategies to counteract tumor-induced immune suppression. Here, we report that tumor-derived extracellular vesicles (tEVs) can induce senescence and suppression in T cells. Programmed death ligand 1 (PD-L1), a key component within tEVs, induced DNA damage and hyperactive lipid metabolism in both human and mouse T cells. This caused an elevated expression of lipid metabolic enzymes and an increase in cholesterol and lipid droplet formation, leading to cellular senescence. At a molecular level, PD-L1 derived from tEVs activated the cAMP-response element binding protein (CREB) and signal transducer and activator of transcription (STAT) signaling, which promoted lipid metabolism and facilitated senescence in human and mouse T cells. Inhibiting EV synthesis in tumors or blocking CREB signaling, cholesterol synthesis, and lipid droplet formation in effector T cells averted the tEV-mediated T cell senescence in vitro and in vivo in cell adoptive transfer and melanoma mouse models. The same treatments also bolstered the antitumor efficacy of adoptive transfer T cell therapy and anti–PD-L1 checkpoint immunotherapy in both human and mouse melanoma models. These studies identified mechanistic links between tumor-mediated immune suppression and potential immunotherapy resistance, and they provide new strategies for cancer immunotherapy.
- Open Access
- 10 January 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (2) , 108180
Prenylation-dependent membrane localization of a deubiquitinating enzyme and its role in regulating G protein–mediated signaling in yeast
- 10 January 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (2) , 108180
Open AccessPrenylation-dependent membrane localization of a deubiquitinating enzyme and its role in regulating G protein–mediated signaling in yeast
- Open Access
- 1 January 2025
- Published by Discovery Medicine in Discovery Medicine
- Vol. 37 (199) , 1423-1433
Recent Development of Immunotherapy for Treating Glioblastoma With a Focus on CAR-T Cells
Glioblastoma remains one of the most aggressive and treatment-resistant brain tumors, with current standard-of-care therapies offering limited survival benefits. Immunotherapy has emerged as a promising avenue to enhance anti-tumor immunity, with chimeric antigen receptor T (CAR-T) cell therapy gaining significant attention. While CAR-T therapies have demonstrated remarkable success in hematologic malignancies, their application in glioblastoma faces several challenges, including tumor heterogeneity, an immunosuppressive tumor microenvironment, limited blood-brain barrier penetration, T-cell exhaustion, and potential neurotoxicity. This review explores recent advancements in CAR-T therapy for glioblastoma, focusing on key tumor-associated antigens and innovative strategies to overcome treatment barriers. These include multi-antigen targeting, checkpoint inhibition, locoregional CAR-T delivery, synNotch, personalized CAR-T systems, and combination approaches with oncolytic viruses. We also discuss future directions for optimizing efficacy and safety. As the field advances, integrating synthetic biology and personalized antigen selection may further refine CAR-T therapy, offering renewed hope for glioblastoma patients.
- 1 January 2025
- Published by Discovery Medicine in Discovery Medicine
- Vol. 37 (199) , 1423-1433
Open AccessRecent Development of Immunotherapy for Treating Glioblastoma With a Focus on CAR-T Cells
Glioblastoma remains one of the most aggressive and treatment-resistant brain tumors, with current standard-of-care therapies offering limited survival benefits. Immunotherapy has emerged as a promising avenue to enhance anti-tumor immunity, with chimeric antigen receptor T (CAR-T) cell therapy gaining significant attention. While CAR-T therapies have demonstrated remarkable success in hematologic malignancies, their application in glioblastoma faces several challenges, including tumor heterogeneity, an immunosuppressive tumor microenvironment, limited blood-brain barrier penetration, T-cell exhaustion, and potential neurotoxicity. This review explores recent advancements in CAR-T therapy for glioblastoma, focusing on key tumor-associated antigens and innovative strategies to overcome treatment barriers. These include multi-antigen targeting, checkpoint inhibition, locoregional CAR-T delivery, synNotch, personalized CAR-T systems, and combination approaches with oncolytic viruses. We also discuss future directions for optimizing efficacy and safety. As the field advances, integrating synthetic biology and personalized antigen selection may further refine CAR-T therapy, offering renewed hope for glioblastoma patients.
- Open Access
- 23 March 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (5) , 104647
The Ycx1 protein encoded by the yeast YDL206W gene plays a role in calcium and calcineurin signaling
- 23 March 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (5) , 104647
Open AccessThe Ycx1 protein encoded by the yeast YDL206W gene plays a role in calcium and calcineurin signaling
- Open Access
- 22 December 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 49 (2) , 1-13
ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment
Clear cell renal cell carcinoma (ccRCC) is a frequent malignant tumor of the kidney which has a dismal prognosis. At present, targeted therapies and immunotherapy have achieved significant results; however, the overall survival rate of patients with ccRCC remains unacceptably poor. It is therefore necessary to find novel therapeutic and diagnostic targets for ccRCC. It has been reported that enolase 2 (ENO2) is an oncogene, although its function in the immune microenvironment and in the growth of ccRCC has yet to be fully elucidated. The present study analyzed the data of patients with ccRCC both from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and from clinical samples obtained from Third Affiliated Hospital of the Second Military Medical University to investigate the role of ENO2 in the progression of ccRCC and the correlation between ENO2 and certain clinical features. It was found that the expression of ENO2 was elevated both in patients with ccRCC retrieved from the GEO and TCGA databases and in clinical ccRCC samples obtained from Third Affiliated Hospital of the Second Military Medical University. In addition, the prognosis of patients was poorer when ENO2 was highly expressed. Gene Ontology (GO) analysis and Gene Set Enrichment Analysis (GSEA) confirmed that ENO2 participated in the regulation of various pathways in ccRCC. In vitro experiments including Cell Counting Kit‑8 cell proliferation assay, Transwell and Matrigel assays confirmed that ENO2 could promote the proliferation and migration of ccRCC cells. Furthermore, a number of immunosuppressive indicators were identified that positively correlated with ENO2 expression. In conclusion, the present study revealed that ENO2 expression promotes the proliferation, invasion and migration of ccRCC cells, and may serve as a novel predictor to evaluate prognosis and the efficacy of immune checkpoint blockade treatment for patients with ccRCC.
- 22 December 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 49 (2) , 1-13
Open AccessENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment
Clear cell renal cell carcinoma (ccRCC) is a frequent malignant tumor of the kidney which has a dismal prognosis. At present, targeted therapies and immunotherapy have achieved significant results; however, the overall survival rate of patients with ccRCC remains unacceptably poor. It is therefore necessary to find novel therapeutic and diagnostic targets for ccRCC. It has been reported that enolase 2 (ENO2) is an oncogene, although its function in the immune microenvironment and in the growth of ccRCC has yet to be fully elucidated. The present study analyzed the data of patients with ccRCC both from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and from clinical samples obtained from Third Affiliated Hospital of the Second Military Medical University to investigate the role of ENO2 in the progression of ccRCC and the correlation between ENO2 and certain clinical features. It was found that the expression of ENO2 was elevated both in patients with ccRCC retrieved from the GEO and TCGA databases and in clinical ccRCC samples obtained from Third Affiliated Hospital of the Second Military Medical University. In addition, the prognosis of patients was poorer when ENO2 was highly expressed. Gene Ontology (GO) analysis and Gene Set Enrichment Analysis (GSEA) confirmed that ENO2 participated in the regulation of various pathways in ccRCC. In vitro experiments including Cell Counting Kit‑8 cell proliferation assay, Transwell and Matrigel assays confirmed that ENO2 could promote the proliferation and migration of ccRCC cells. Furthermore, a number of immunosuppressive indicators were identified that positively correlated with ENO2 expression. In conclusion, the present study revealed that ENO2 expression promotes the proliferation, invasion and migration of ccRCC cells, and may serve as a novel predictor to evaluate prognosis and the efficacy of immune checkpoint blockade treatment for patients with ccRCC.
- Open Access
- 12 October 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (10) , e003217
Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment
Immunotherapeutic drugs including immune checkpoint blockade antibodies have been approved to treat patients in many types of cancers. However, some patients have little or no reaction to the immunotherapy drugs. The mechanisms underlying resistance to tumor immunotherapy are complicated and involve multiple aspects, including tumor-intrinsic factors, formation of immunosuppressive microenvironment, and alteration of tumor and stromal cell metabolism in the tumor microenvironment. T cell is critical and participates in every aspect of antitumor response, and T cell dysfunction is a severe barrier for effective immunotherapy for cancer. Emerging evidence indicates that extracellular vesicles (EVs) secreted by tumor is one of the major factors that can induce T cell dysfunction. Tumor-derived EVs are widely distributed in serum, tissues, and the tumor microenvironment of patients with cancer, which serve as important communication vehicles for cancer cells. In addition, tumor-derived EVs can carry a variety of immune suppressive signals driving T cell dysfunction for tumor immunity. In this review, we explore the potential mechanisms employed by tumor-derived EVs to control T cell development and effector function within the tumor microenvironment. Especially, we focus on current understanding of how tumor-derived EVs molecularly and metabolically reprogram T cell fates and functions for tumor immunity. In addition, we discuss potential translations of targeting tumor-derived EVs to reconstitute suppressive tumor microenvironment or to develop antigen-based vaccines and drug delivery systems for cancer immunotherapy.
- 12 October 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (10) , e003217
Open AccessEmerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment
Immunotherapeutic drugs including immune checkpoint blockade antibodies have been approved to treat patients in many types of cancers. However, some patients have little or no reaction to the immunotherapy drugs. The mechanisms underlying resistance to tumor immunotherapy are complicated and involve multiple aspects, including tumor-intrinsic factors, formation of immunosuppressive microenvironment, and alteration of tumor and stromal cell metabolism in the tumor microenvironment. T cell is critical and participates in every aspect of antitumor response, and T cell dysfunction is a severe barrier for effective immunotherapy for cancer. Emerging evidence indicates that extracellular vesicles (EVs) secreted by tumor is one of the major factors that can induce T cell dysfunction. Tumor-derived EVs are widely distributed in serum, tissues, and the tumor microenvironment of patients with cancer, which serve as important communication vehicles for cancer cells. In addition, tumor-derived EVs can carry a variety of immune suppressive signals driving T cell dysfunction for tumor immunity. In this review, we explore the potential mechanisms employed by tumor-derived EVs to control T cell development and effector function within the tumor microenvironment. Especially, we focus on current understanding of how tumor-derived EVs molecularly and metabolically reprogram T cell fates and functions for tumor immunity. In addition, we discuss potential translations of targeting tumor-derived EVs to reconstitute suppressive tumor microenvironment or to develop antigen-based vaccines and drug delivery systems for cancer immunotherapy.
- Open Access
- 11 December 2020
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 7
Activation of a Mitogen-Activated Protein Kinase Hog1 by DNA Damaging Agent Methyl Methanesulfonate in Yeast
Hog1 is a mitogen-activated protein kinase in yeast that primarily regulates cellular responses to hyperosmolarity stress. In this study, we have examined the potential involvement of Hog1 in mediating cellular responses to DNA damaging agents. We find that treatment of yeast cells with DNA damaging agent methyl methanesulfonate (MMS) induces a marked and prolonged Hog1 activation. Distinct from stressors such as arsenite that activates Hog1 via inhibiting its phosphatases, activation of Hog1 by MMS is phosphatase-independent. Instead, MMS impairs a critical phosphor-relay process that normally keeps Hog1 in an inactive state. Functionally, MMS-activated Hog1 is not translocated to the nucleus to regulate gene expression but rather stays in the cytoplasm and regulates MMS-induced autophagy and cell adaptation to MMS stress. These findings reveal a new role of Hog1 in regulating MMS-induced cellular stress.
- 11 December 2020
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 7
Open AccessActivation of a Mitogen-Activated Protein Kinase Hog1 by DNA Damaging Agent Methyl Methanesulfonate in Yeast
Hog1 is a mitogen-activated protein kinase in yeast that primarily regulates cellular responses to hyperosmolarity stress. In this study, we have examined the potential involvement of Hog1 in mediating cellular responses to DNA damaging agents. We find that treatment of yeast cells with DNA damaging agent methyl methanesulfonate (MMS) induces a marked and prolonged Hog1 activation. Distinct from stressors such as arsenite that activates Hog1 via inhibiting its phosphatases, activation of Hog1 by MMS is phosphatase-independent. Instead, MMS impairs a critical phosphor-relay process that normally keeps Hog1 in an inactive state. Functionally, MMS-activated Hog1 is not translocated to the nucleus to regulate gene expression but rather stays in the cytoplasm and regulates MMS-induced autophagy and cell adaptation to MMS stress. These findings reveal a new role of Hog1 in regulating MMS-induced cellular stress.
- Open Access
- 1 December 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (49) , 18836-18845
Phosphorylation of the Gα protein Gpa2 promotes protein kinase A signaling in yeast
- 1 December 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (49) , 18836-18845
Open AccessPhosphorylation of the Gα protein Gpa2 promotes protein kinase A signaling in yeast